Novo’s Insulin Icodec Hypoglycemia Risk Outweighs Limited Benefit In Type 1 Diabetes–FDA Panel

 
• By Sue Sutter
  
Scales
The risks of insulin icodec outweigh its benefits in type 1 diabetes, the adcomm said. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers